153 related articles for article (PubMed ID: 25692618)
1. Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?
Ley AM; Chau CH; Figg WD
Cancer Biol Ther; 2015; 16(1):19-20. PubMed ID: 25692618
[TBL] [Abstract][Full Text] [Related]
2. A peek into the atomic details of thalidomide's clinical effects.
Bhogaraju S; Dikic I
Nat Struct Mol Biol; 2014 Sep; 21(9):739-40. PubMed ID: 25192261
[No Abstract] [Full Text] [Related]
3. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Bodera P; Stankiewicz W
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide-a notorious sedative to a wonder anticancer drug.
Zhou S; Wang F; Hsieh TC; Wu JM; Wu E
Curr Med Chem; 2013; 20(33):4102-8. PubMed ID: 23931282
[TBL] [Abstract][Full Text] [Related]
5. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
Yamamoto T; Shibata N; Sukeguchi D; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H; Tanaka M; Obata T; Sasaki T
Bioorg Med Chem Lett; 2009 Jul; 19(14):3973-6. PubMed ID: 19297157
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of thalidomide and its derivatives.
Ito T; Handa H
Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
[TBL] [Abstract][Full Text] [Related]
8. IMiDs New and Old.
Yamshon S; Ruan J
Curr Hematol Malig Rep; 2019 Oct; 14(5):414-425. PubMed ID: 31302872
[TBL] [Abstract][Full Text] [Related]
9. Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents.
Nutt MJ; Stewart SG
Drug Discov Today; 2024 Jun; 29(6):104010. PubMed ID: 38704021
[TBL] [Abstract][Full Text] [Related]
10. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Sissung TM; Thordardottir S; Gardner ER; Figg WD
Anticancer Agents Med Chem; 2009 Dec; 9(10):1058-69. PubMed ID: 19719457
[TBL] [Abstract][Full Text] [Related]
11. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
12. Low-dose thalidomide in myeloma: efficacy and biologic significance.
Durie BG
Semin Oncol; 2002 Dec; 29(6 Suppl 17):34-8. PubMed ID: 12520483
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide mimics uridine binding to an aromatic cage in cereblon.
Hartmann MD; Boichenko I; Coles M; Zanini F; Lupas AN; Hernandez Alvarez B
J Struct Biol; 2014 Dec; 188(3):225-32. PubMed ID: 25448889
[TBL] [Abstract][Full Text] [Related]
14. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
15. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide Teratogenic Effects Linked to Degradation of SALL4: After 60 years, researchers have now shed light on the mechanism underlying thalidomide's devastating teratogenic effects.
Am J Med Genet A; 2018 Dec; 176(12):2538-2539. PubMed ID: 30597765
[No Abstract] [Full Text] [Related]
17. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
[TBL] [Abstract][Full Text] [Related]
19. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.
Kenyon BM; Browne F; D'Amato RJ
Exp Eye Res; 1997 Jun; 64(6):971-8. PubMed ID: 9301478
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide treatment in multiple myeloma.
Strasser K; Ludwig H
Blood Rev; 2002 Dec; 16(4):207-15. PubMed ID: 12350364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
